Skip to main content
Premium Trial:

Request an Annual Quote

SeraCare to Acquire Serologicals Celliance Unit for $3.7M in Bid to Boost Dx Reagent Play

NEW YORK, Nov. 29 (GenomeWeb News) - SeraCare Life Sciences will acquire Serologicals' Celliance subsidiary for $3.7 million in cash and "certain liabilities," the companies said today


SeraCare, based in Oceanside, Calif., will buy Celliance's Milford, Mass.-based diagnostic manufacturing facilities and its product lines.


Celliance, which in  October acquired gene-expression technology from Innovata, primarily offers products for cell culture and diagnostic applications. The acquisition is aimed at increasing SeraCare's footprint in molecular diagnostic reagents, diagnostic intermediates, and substrates, President and CEO Michael Crowley said in a statement.


The acquisition is expected to close in January, SeraCare said. Further details were not disclosed.


SeraCare has facilities in Cambridgeand Bridgewater, Mass.; Frederickand Gaithersburg, Md.; and Hatboro, Penn.It sells plasma-based therapeutic products, diagnostic products, and reagents; cell culture products; specialty plasmas; in vitro stabilizers; and a clinical sample repository for use in drug discovery and development.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.